Offerings - ExpreS2ion Biotech Holding AB (publ) – Rights issue of SEK 131m

Arctic Securities is acting as financial advisor in relation to the rights issue in ExpreS2ion Biotech Holding AB (publ). ExpreS2ion Biotech Holding AB (publ) is referred to as “Expres2ion” or “the Company”. Shareholders have pre-emptive rights to subscribe for units. Three (1) existing shares held on the record date of October 1, 2020 entitles to one (1) unit consisting of two (2) new shares and one (1) warrant of series TO4 free of charge and one (1) warrant of series TO5 free of charge. Subscription price of SEK 24 per unit, corresponding to SEK 12 per share. The subscription period runs October 5 – October 19, 2020. Three (3) warrants of series TO4 entitles the holder to subscribe for one (1) share in the Company during the period from April 12, 2021 to April 26, 2021. Strike price for warrants will correspond to 70 percent of the VWAP of the Company's share on Nasdaq First North Growth Market during the period from March 29, 2021 to April 9, 2021, but at least SEK 6 and a maximum of SEK 22 per share. Three (3) warrants of series TO5 entitles the holder to subscribe for one (1) share in the Company during the period from September 6, 2021 to September 20, 2021. Strike price for warrants will correspond to 70 percent of the VWAP of the Company's share on Nasdaq First North Growth Market during the period from August 23, 2021 to September 3, 2021, but at least SEK 6 and a maximum of SEK 25 per share. The rights issue is secured up to 100 percent through subscription- and guarantee undertakings. A Swedish prospectus and subscription note will be available before the subscription period on Expres2ion’s website, www.expres2ionbio.com and Arctic Securities website.